Dive Brief: The Food and Drug Administration has granted a full approval to Gilead’s COVID-19 drug Veklury, making it the first medicine to win a standard clearance from the agency to treat the disease caused by the new coronavirus. The FDA authorized Veklury for emergency use in May, a declaration that’s only valid during a… Read More »
Compared with the spate of multibillion-dollar buyouts last year, biopharma M&A has been relatively quiet in 2020—until last week, when Gilead Sciences surprised the market with its $ 21 billion purchase of Immunomedics. Now, two sets of new cancer data from Immunomedics’ first-in-class antibody-drug conjugate Trodelvy offer a glimpse into why Gilead paid such big money… Read More »
UnitedHealthcare has a history of limiting HIV drug costs, including offering cash incentives to patients who opt for low-priced regimens. Now, in a potentially major blow to HIV giant Gilead Sciences, the insurer has set its eyes on one of the California drugmaker’s new therapies. Gilead’s new HIV PrEP option, Descovy, will no longer be covered… Read More »
The Food and Drug Administration on Friday cleared an experimental drug from Gilead for emergency use in treating COVID-19, acting quickly following announcement on Wednesday of encouraging results from a crucial government-run study. Results from the study, which was led by the National Institutes for Allergy and Infectious Diseases, showed treatment with remdesivir led to… Read More »
Days after U.S. officials and others reported the first positive controlled data for Gilead’s remdesivir in COVID-19, the FDA has given the drug an emergency use authorization. President Donald Trump and Gilead CEO Daniel O’Day made the announcement Friday afternoon at the White House, according to CNBC’s Meg Tirrell. An FDA fact sheet on the… Read More »